Novel Triple-dose Tuberculosis Retreatment Regimen

• Status: Recruiting
• Trial end date: 2024-11-01

Summary

To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent Tuberculosis (TB).

• Phase: Phase 3

Details

• Lead Sponsor: Institute of Tropical Medicine, Belgium
• Collaborator: Damien Foundation
• Treatments: Ethambutol; Isoniazid; Pyrazinamide; Rifampin